Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04526691
Title Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Daiichi Sankyo, Inc.

lung non-small cell carcinoma


Cisplatin + Datopotamab Deruxtecan + Pembrolizumab

Carboplatin + Datopotamab Deruxtecan + Pembrolizumab

Datopotamab Deruxtecan + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | ITA | ESP

Additional content available in CKB BOOST